li001

Dostarlimab Continues to Show Strong Results in Locally Advanced Rectal Cancer

Treatment /

The phase 2 AZUR-1 trial has met its main goal, showing that dostarlimab (Jemperli) alone can produce a lasting complete response in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer. An interim analysis found that many patients had no detectable signs of cancer 12 months or longer after starting treatment. The results suggest that […]

Dostarlimab Continues to Show Strong Results in Locally Advanced Rectal Cancer Read More »

Researchers Discover New Pathway That Fuels Cancer Growth

Research Advances /

Researchers have identified a new metabolic pathway that helps cancer cells grow and spread. The study, published in Nature Communications, reveals how changes in cell metabolism can directly activate genes that drive tumor progression. The team found that under stress, two mitochondrial enzymes, ACO2 and IDH2, move into the cell nucleus and produce acetyl CoA.

Researchers Discover New Pathway That Fuels Cancer Growth Read More »

FDA Approves Ennumo, the Eighth Neulasta Biosimilar, for Supportive Cancer Care

Drug Approvals /

The FDA has approved Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta (pegfilgrastim), for adults and children. Developed by Accord BioPharma, it is the eighth pegfilgrastim biosimilar approved in the United States. The drug is supplied as a single-dose prefilled syringe and helps reduce the risk of infection by increasing white blood cell production in patients receiving

FDA Approves Ennumo, the Eighth Neulasta Biosimilar, for Supportive Cancer Care Read More »

FDA Expands Pembrolizumab Plus Enfortumab Vedotin for Perioperative Bladder Cancer Treatment

Drug Approvals /

The FDA has expanded the approval of pembrolizumab (Keytruda) or the subcutaneous formulation Keytruda Qlex, in combination with enfortumab vedotin (Padcev), for adults with muscle-invasive bladder cancer (MIBC). The regimen can now be used before surgery (neoadjuvant therapy) and after bladder removal surgery (adjuvant therapy) for all patients who are eligible for surgery, regardless of

FDA Expands Pembrolizumab Plus Enfortumab Vedotin for Perioperative Bladder Cancer Treatment Read More »

FDA Approves Subcutaneous Sarclisa Escena With Wearable Injector for Multiple Myeloma

Drug Approvals /

The FDA has approved a subcutaneous (under-the-skin) formulation of isatuximab-irfc (Sarclisa Escena) for all indications previously covered by the intravenous (IV) version in multiple myeloma. The treatment can be administered using the wearable CirCLIQ on-body delivery system or a manual syringe, making it the first FDA-approved cancer therapy delivered through an on-body injector. The approval

FDA Approves Subcutaneous Sarclisa Escena With Wearable Injector for Multiple Myeloma Read More »

Ateganosine Plus Cemiplimab Shows Promising Activity in Advanced Lung Cancer

Clinical Trails /

Interim results from the phase 2 THIO-101 trial show that the investigational drug ateganosine (THIO), followed by the PD-1 inhibitor cemiplimab (Libtayo), achieved a 90.5% disease control rate in heavily pretreated patients with advanced non-small cell lung cancer (NSCLC). Among 21 patients evaluated, 19 experienced either a complete response, partial response, or stable disease. This

Ateganosine Plus Cemiplimab Shows Promising Activity in Advanced Lung Cancer Read More »

Zoldonrasib Combinations Show Strong Early Results in RAS G12D Pancreatic Cancer

Treatment /

New data show that zoldonrasib (RMC-9805), an oral RAS G12D-targeted therapy, produced promising results in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) carrying a RAS G12D mutation. In previously untreated patients, zoldonrasib combined with modified FOLFIRINOX achieved an objective response rate of 82%, while the combination with gemcitabine plus nab-paclitaxel reached 61%. Disease control rates

Zoldonrasib Combinations Show Strong Early Results in RAS G12D Pancreatic Cancer Read More »

Updated Analysis Suggests DCVax-L Offers Greater Survival Benefit in Glioblastoma

Treatment /

New data suggest that the survival benefit of DCVax-L for patients with glioblastoma (GBM) is greater than previously reported. The original phase 3 analysis showed that DCVax-L improved median overall survival by 2.8 months. However, a new analysis using individual patient data from three randomized clinical trials found that the actual survival benefit ranged from

Updated Analysis Suggests DCVax-L Offers Greater Survival Benefit in Glioblastoma Read More »

Ensartinib Significantly Reduces Recurrence Risk in ALK-Positive Lung Cancer After Surgery

Treatment /

Results from the phase 3 ELEVATE trial show that ensartinib (Ensacove) significantly reduced the risk of cancer recurrence in patients with completely resected stage IB to IIIB ALK-positive non-small cell lung cancer (NSCLC) after chemotherapy. Among patients with stage II to IIIB disease, the 24-month disease-free survival (DFS) rate was 86.4% with ensartinib, compared with

Ensartinib Significantly Reduces Recurrence Risk in ALK-Positive Lung Cancer After Surgery Read More »

Study Identifies Protective Role of IgG Antibodies in Pancreatic Cancer

Research Advances /

A new study suggests that circulating IgG antibodies may help slow the growth and spread of pancreatic ductal adenocarcinoma (PDAC) by maintaining the tumor’s surrounding tissue and supporting anti-cancer immune responses. Using genetically engineered mouse models, researchers found that mice lacking circulating antibodies developed pancreatic tumors twice as fast and survived only about half as

Study Identifies Protective Role of IgG Antibodies in Pancreatic Cancer Read More »